Ehlers-Danlos Syndrome (EDS) is a group of connective tissue disorders characterized by defects in collagen production, which leads to symptoms like hypermobility, fragile skin, and vascular complications. One important but often overlooked complication of EDS is its impact on the digestive system, particularly gastroparesis. Gastroparesis is a condition where the stomach's ability to move food into the small intestine is slowed or impaired without an actual physical blockage. In patients with EDS, this dysfunction occurs because the connective tissue that supports the stomach and surrounding organs becomes abnormally stretched or damaged. This can affect the stomach's muscular contractions and the nerves that regulate digestion. Key to understanding how EDS causes gastroparesis is the role of the vagus nerve, which controls much of the digestive process, including the opening and closing of sphincters and the coordination of stomach emptying. In EDS, the connective tissues protecting this nerve can be compromised, leading to poor electrical signaling and impaired motility. Additionally, abnormal scarring and connective tissue laxity can lead to stomach dysfunction either primarily or secondarily. Patients may experience symptoms such as nausea, vomiting, early satiety, and abdominal pain. Some research and patient reports also highlight that viral illnesses like COVID-19 can exacerbate gastroparesis symptoms in EDS due to increased nerve inflammation or damage. Understanding these mechanisms is crucial for managing EDS-related gastroparesis. Therapies may include dietary changes, medications that enhance gastric motility, and careful monitoring of symptoms to improve quality of life. Increased awareness helps both patients and healthcare providers recognize the complex interplay between connective tissue disorders and gastrointestinal dysfunction, guiding better treatment strategies.